PT-141 (Bremelanotide) vs AOD-9604: Cost, Access, and What Women Actually Need to Know

What Are These Two Peptides and Why Do Women Ask About Both?

PT-141 and AOD-9604 occupy completely different corners of women's health, yet they appear together in online forums and telehealth marketing because both are peptides administered by injection and both circulate in the same wellness-adjacent spaces. Understanding what separates them is more useful than comparing them side by side.

PT-141, the trade name for bremelanotide, is a synthetic melanocortin receptor agonist approved by the FDA in June 2019 under the brand name Vyleesi. It targets the melanocortin 4 receptor (MC4R) in the central nervous system to increase sexual desire. AOD-9604, also called HGH fragment 176-191, is a synthetic peptide derived from the C-terminal end of human growth hormone. It has no FDA approval for any condition and is classified as a research compound.

Women encounter both in weight-loss clinics, compounding pharmacy catalogs, and online peptide communities, which is where the confusion starts. One has a defined, studied female-specific indication. The other does not.

The Mechanism Gap Is Large

PT-141 acts centrally. It crosses the blood-brain barrier and activates MC4R receptors in hypothalamic pathways that regulate sexual arousal, which is why it generates a desire response rather than a purely vascular one. This mechanism distinguishes it from PDE5 inhibitors and explains why it was developed specifically for women, whose sexual dysfunction is more often desire-based than blood-flow-based.

AOD-9604 acts peripherally on fat tissue. Heffernan et al. Demonstrated in 2001 that this fragment of human growth hormone stimulates lipolysis and inhibits lipogenesis in animal models without activating the growth hormone receptor. That finding is the scientific basis for every claim that AOD-9604 is a "fat-burning peptide," but the leap from rodent adipose tissue to meaningful fat loss in human women has not been bridged by randomized controlled trials.

Who Is Searching for Each?

Women with HSDD, a condition affecting an estimated 10 percent of premenopausal women and characterized by persistently low sexual desire causing personal distress, are the intended audience for PT-141. Women looking for adjunctive weight management support, particularly those in perimenopause or post-menopause who notice shifts in fat distribution, tend to find AOD-9604. These are not the same woman or the same problem.

PT-141 (Bremelanotide): The Clinical Evidence in Women

The key evidence for PT-141 in women comes from the RECONNECT trial program. RECONNECT was a pair of phase 3, randomized, double-blind, placebo-controlled studies published in Obstetrics and Gynecology in 2019. Across both studies, premenopausal women with HSDD who used bremelanotide 1.75 mg subcutaneously as needed showed statistically significant increases in satisfying sexual events and decreases in distress scores compared with placebo. This is the level of evidence that earns FDA approval.

What RECONNECT Actually Found

The trials enrolled premenopausal women aged 18 to 50 with a diagnosis of generalized, acquired HSDD. The primary endpoints were change from baseline in the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm total score. Women using bremelanotide reported a mean increase of approximately 0.5 points on the desire subscale and a clinically meaningful reduction in distress, with the drug performing significantly better than placebo on both measures. The number needed to treat for one additional satisfying sexual event per month was approximately 12, which is modest but consistent with the effect sizes seen in other female sexual dysfunction trials.

Dosing and Administration

The approved dose is 1.75 mg injected subcutaneously into the abdomen or thigh 45 minutes before anticipated sexual activity. No more than one dose per 24-hour period and no more than eight doses per month is the recommended schedule. The injection-based, on-demand format matters for women who want to use it situationally rather than taking a daily pill.

Side Effects Women Report Most

Nausea occurs in approximately 40 percent of users and is the most common reason for discontinuation. Flushing and headache follow. Transient blood pressure increases of 2 to 4 mmHg systolic lasting 8 to 12 hours occur in most users, which means women with uncontrolled hypertension should not use it. Hyperpigmentation of the face, gums, and breasts develops with chronic use because bremelanotide activates melanocortin 1 receptors as well.

Life Stage Considerations for PT-141

PT-141 is studied and approved exclusively for premenopausal women. No phase 3 trial has enrolled postmenopausal women, so its efficacy in that group is extrapolated, not directly established. Women in perimenopause with declining desire secondary to estrogen and androgen shifts may have a desire disorder driven by hormonal changes rather than the central melanocortin pathway, and in those cases, addressing the hormonal substrate with menopause hormone therapy may be more appropriate before or alongside bremelanotide.

Women with PCOS are not specifically excluded from use, but the nausea risk and blood pressure effects deserve attention given the higher rates of metabolic syndrome in this population.

AOD-9604: What the Evidence Actually Shows

AOD-9604 has a much thinner evidence base, and being honest about that is the right starting point.

The Animal Data Foundation

Heffernan and colleagues published in Endocrinology in 2001 that AOD-9604 significantly reduced body weight and fat mass in obese mice, and that it did so through stimulation of lipolysis and inhibition of lipogenesis without activating the IGF-1 axis or causing the glucose intolerance associated with exogenous growth hormone. This was a genuinely interesting preclinical finding and it justified moving into early human work.

The Human Data Gap

Metabolic Pharmaceuticals ran phase 2 trials in the early 2000s. Those trials did not meet their primary endpoints for statistically significant fat loss in overweight adults when the peptide was administered orally. The company's phase 3 program was not completed, and AOD-9604 was never approved by the FDA or TGA for any indication. The FDA has not classified AOD-9604 as an approved new drug, which means compounded versions cannot legally be prepared for individual patients under the framework that governs FDA-approved drugs.

What This Means for Women Specifically

No published trial has specifically enrolled women with PCOS, perimenopausal weight gain, postpartum body composition changes, or any female-specific metabolic phenotype to study AOD-9604. Every claim about its benefit in these populations is extrapolated from rodent data or anecdote.

Women in perimenopause gain an average of 1.5 kg per year during the transition, with fat preferentially redistributing to the abdomen. This is a real and distressing change, but the evidence that AOD-9604 addresses it specifically does not exist.

Women with insulin resistance or PCOS seeking a metabolic edge deserve to know that the compound has not been tested in those populations and that its proposed mechanism (GH-fragment lipolysis) has not been validated against insulin-sensitizing agents like metformin or lifestyle intervention in any comparative trial.

Cost and Access: A Real-World Comparison

The cost difference between these two compounds is large, but so is the regulatory and safety context that surrounds each price point. The table below organizes the access field for women navigating this decision.

| Factor | PT-141 (Bremelanotide) | AOD-9604 | |---|---|---| | FDA status | Approved (NDA 210557) | Not approved; research use only | | Typical cash price | $800-$1,000/month | $60-$200/vial (unregulated) | | Insurance coverage | Rarely covered; prior auth required | Never covered | | Compounding available | Yes, under 503A/503B regulations | Sold as research chemical; not legal for compounding as Rx | | Prescription required | Yes | Sold without prescription as "not for human use" | | Quality control | FDA-regulated manufacturing | No required third-party testing | | Telehealth access | Available via licensed providers | Available via unregulated wellness platforms |

The True Cost of PT-141

At $800 to $1,000 per month for eight doses, PT-141 is expensive. Some compounding pharmacies prepare bremelanotide under 503A regulations at costs of $150 to $300 per kit, which makes it more accessible but requires verifying the pharmacy's FDA-registered status. GoodRx and manufacturer savings programs may reduce the brand-name cost for eligible women. The on-demand dosing structure means women who use it two or three times per month spend considerably less than the monthly maximum.

The True Cost of AOD-9604

The low sticker price of AOD-9604, typically $60 to $200 per vial, does not account for what you do not get: no dosing validation, no sterility certificate you can rely on, no pharmacist review of interactions, and no physician accountability. Vials sold for research use carry a legal disclaimer that they are not intended for human use. Women who inject them anyway are accepting unknown purity risks.

Pregnancy, Lactation, and Contraception

This section is mandatory for both compounds and the information here is not optional reading.

PT-141 in Pregnancy

Bremelanotide is contraindicated in pregnancy. Animal reproductive studies showed decreased implantation rates, fetal loss, and reduced fetal weight at doses used in rodent models. No adequate, well-controlled studies exist in pregnant women. Because the drug is used on demand rather than continuously, inadvertent early-pregnancy exposure is a realistic risk if a woman does not know she has conceived. Women of reproductive age should use reliable contraception during bremelanotide use and perform a pregnancy test if a period is missed.

The FDA assigns bremelanotide to a category where animal data show fetal risk and human data are absent. Use during pregnancy should be discontinued immediately if pregnancy is confirmed.

PT-141 and Lactation

No data on transfer of bremelanotide into human breast milk exists. Given the lack of any safety information, bremelanotide should not be used by women who are breastfeeding. The drug's lipophilic properties suggest some milk transfer is plausible, and the neonatal melanocortin system is active during early development, which is a reason for caution.

AOD-9604 in Pregnancy and Lactation

There is no published reproductive safety data for AOD-9604 in humans. None. Women who are pregnant, planning to become pregnant, or breastfeeding should not use this compound under any circumstances.

A Note for Women Trying to Conceive

Women in the trying-to-conceive (TTC) window should avoid both compounds. HSDD in women who are TTC may have a hormonal basis (low estrogen, low testosterone, elevated prolactin, thyroid dysfunction) that is worth evaluating and treating before considering a melanocortin agonist. A reproductive endocrinologist or women's health specialist can order the appropriate panel.

Who Is PT-141 Right For, and Who Should Avoid It?

Right For

• Premenopausal women with a confirmed HSDD diagnosis (generalized, acquired)
• Women who have already addressed relationship, psychological, and hormonal contributors to low desire and still experience the problem
• Women without uncontrolled hypertension, cardiovascular disease, or high nausea sensitivity
• Women who prefer on-demand rather than daily treatment

Not Right For

• Postmenopausal women (no phase 3 data; the hormonal environment is different)
• Women currently pregnant or breastfeeding
• Women with uncontrolled hypertension (transient BP rise is consistent and documented)
• Women whose low desire is primarily situational or relationship-based
• Women looking for a weight management tool (this is not what PT-141 does)

Who Is AOD-9604 Right For, and Who Should Avoid It?

Might Consider With Significant Caveats

• Women who have exhausted evidence-based options for metabolic health and want to participate in an informed off-label experiment under close medical supervision
• Women whose clinician is able to source third-party tested material and monitor labs

Should Avoid

• Pregnant women, women breastfeeding, women TTC: no safety data, full stop
• Women with a history of cancer or family history of growth-related cancers (the GH-fragment lineage warrants caution even though AOD-9604 does not activate GHR)
• Women seeking a substitute for lifestyle change or FDA-approved obesity medicines like semaglutide or tirzepatide, which have substantial randomized trial evidence in women

The Evidence Gap Specific to Women

Women were historically underrepresented in peptide and metabolic drug trials. The RECONNECT program is a meaningful exception: it enrolled only women and was designed around female sexual function endpoints, making its findings directly applicable to the women reading this article. AOD-9604 research went in the opposite direction. Its preclinical work used rodent models and its early human trials included mixed-sex cohorts without sex-stratified reporting.

As WomanRx clinical reviewer Dr. Elena Vasquez, MD, notes: "The absence of female-specific data for AOD-9604 is not a minor footnote. Women have different adipose distribution patterns, different hormonal modulation of lipolysis, and a different relationship between growth hormone axis activity and metabolic risk across the reproductive lifespan. Extrapolating rodent data or mixed-sex adult data to a perimenopausal woman asking about belly fat is not good medicine."

This gap matters practically. Perimenopausal and postmenopausal women have reduced growth hormone pulsatility compared with younger women. Whether a GH-fragment peptide behaves the same way in that hormonal environment is unknown.

Switching Between PT-141 and AOD-9604

Women occasionally ask whether they can switch from one to the other, or use both simultaneously. The answer requires clarity about what each does.

These are not interchangeable drugs targeting the same condition. PT-141 addresses desire and sexual satisfaction. AOD-9604 is proposed to affect fat metabolism. A woman using PT-141 for HSDD who decides to stop has no metabolic reason to start AOD-9604, and vice versa. There is no pharmacokinetic interaction data because no study has tested them together, but the absence of data is itself a reason for caution rather than reassurance.

Women who are dissatisfied with PT-141 due to nausea or cost should discuss flibanserin (Addyi), the oral daily melanocortin-modulating alternative for HSDD, with their prescriber. Women dissatisfied with AOD-9604's lack of effect have a growing list of FDA-approved GLP-1 receptor agonists with demonstrated weight and metabolic benefit in women.

The Regulatory and Quality Control Reality

The FDA approved bremelanotide through the standard New Drug Application pathway (NDA 210557). That process required manufacturing quality standards, pharmacovigilance systems, and post-marketing surveillance. Women using brand-name Vyleesi or a 503A-compounded version from a licensed pharmacy are within a regulatory framework that provides some accountability.

AOD-9604 exists entirely outside that framework. Independent testing of research peptides sold online has found dosing inaccuracies and contamination in a significant proportion of samples. Women who inject any compound of unknown purity are accepting risks that no telehealth provider or wellness platform can fully mitigate.

Cost-Effectiveness Framing for Women Making Real Decisions

At $800 per month, PT-141 at maximum use is expensive but traceable. A woman using it twice per month from a compounding pharmacy at $175 per kit is spending $350 per month for a documented, FDA-approved treatment with a mechanism validated in phase 3 trials enrolling women like her.

At $120 for a vial of AOD-9604 from an online research supplier, the dollar figure is low. The cost in unknown biological risk, the absence of quality assurance, and the certainty of no insurance coverage for any complications are harder to price.

For women managing real budgets, the more useful comparison is probably not PT-141 vs AOD-9604 but PT-141 vs flibanserin for HSDD, or AOD-9604 vs semaglutide for metabolic support. Both of those comparisons have clinical data to work with.

Summary Comparison Table

| Attribute | PT-141 (Bremelanotide) | AOD-9604 | |---|---|---| | Target condition | HSDD (sexual desire) | Proposed fat metabolism support | | FDA approval | Yes (2019) | No | | Phase 3 RCT in women | Yes (RECONNECT, Obstet Gynecol 2019) | No | | Mechanism | Central MC4R agonism | Peripheral lipolysis, GH-receptor independent | | Pregnancy safety | Contraindicated | No data; avoid | | Lactation safety | No data; avoid | No data; avoid | | Typical monthly cost | $800-$1,000 brand; $150-$350 compounded | $60-$200/vial, unregulated | | Insurance coverage | Rarely | Never | | Life stage studied | Premenopausal women specifically | No female-specific data | | Primary side effect | Nausea (~40%), BP increase | Unknown in humans at scale |